-
公开(公告)号：US20240239673A1
公开(公告)日：2024-07-18
申请号：US18562040
申请日：2022-05-19
IPC分类号： C01C1/02
CPC分类号： C01C1/02
摘要： A method for producing ammonia nitrogen, using dinitrogen reduction in the presence of a compound (I), which includes at least one element from group 13 of the periodic table of elements, The method includes a step of bringing into contact with dinitrogen a composition that includes the compound (I), a reducing agent, and an organ solvent and a hydrolysis step in an acid medium. Also the use of this compound (I) for dinitrogen reduction.
-
公开(公告)号：US20220288040A1
公开(公告)日：2022-09-15
申请号：US17639477
申请日：2020-08-31
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITÉ TOULOUSE III - PAUL SABATIER , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) , UNIVERSITÉ DE PARIS
IPC分类号： A61K31/435 , A61K31/519 , A61K45/06 , A61P35/02
摘要： Acute myeloid leukemia (AML) are heterogeneous malignancies arising from the multistep transformation of bone marrow immature cells. The inventors showed that RAS pathway mutations were detected in 40% of FLT3- and NPM1-unmutated AML cases and correlated with higher white blood cell count, blast cell percentage and reduced survival after intensive therapy. Building on genetic models of RAS activation, they highlighted the leukemogenic potential of RAS pathway alterations, and the efficacy and limitations of MEK inhibitors in this context. From high-content chemical screens, the inventors unraveled pyrvinium pamoate—an anthelminthic drug approved in human patients—as displaying a preferential cytotoxicity against RAS activated cells. This potential clinical candidate demonstrated a robust synergistic activity with the MEK inhibitor trametinib, including in primary samples from AML patients. Together the data suggest that RAS pathway altered cases may represent a specific AML subtype, in which the anti-leukemic molecule pyrvinium pamoate may represent a new promising therapeutic strategy.
-
公开(公告)号：US12011466B2
公开(公告)日：2024-06-18
申请号：US17625220
申请日：2020-07-07
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ TOULOUSE III—PAUL SABATIER , ECOLE NATIONALE VÉTÉRINAIRE DE TOULOUSE , INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
IPC分类号： A61K35/741 , A61P1/00 , C12N1/20 , C12N9/48 , C12R1/19
CPC分类号： A61K35/741 , A61P1/00 , C12N1/205 , C12N9/485 , C12R2001/19
摘要： The invention relates to the field of modified Escherichia coli strain Nissle 1917 (EcN) and its use for treating gastro-intestinal disorders. The invention is based on the study of the mechanisms implicated in the probiotic properties of the Escherichia coli strain Nissle 1917 (EcN). This study has allowed the inventors to decouple the probiotic activity of EcN from its genotoxic activity by demonstrating that EcN ClbP protein, the enzyme that activates the genotoxin colibactin, is also required for the siderophore-microcins activity of probiotic EcN, but interestingly, not its enzymatic domain that cleaves precolibactin to form active colibactin. Furthermore, inventors demonstrate in an in vivo animal model infected by a bacterial pathogen that administration of an EcN modified strain with clbP gene encoding ClbP protein inactive for the peptidase domain, is non-genotoxic (do not produce colibactin) but keeps the bacterial antagonist activity, and reduces colonization and virulence of the pathogen by maintaining the siderophore-microcin production. Thus this study opens the way to safe use of EcN and accordingly the present invention provides an Escherichia coli strain Nissle 1917 (EcN) bacterium carrying a gene encoding ClbP protein which is inactive for the peptidase domain, and its use as a drug and more particularly for use in the treatment of gastro-intestinal disease.
-
公开(公告)号：US20230365265A1
公开(公告)日：2023-11-16
申请号：US18316334
申请日：2023-05-12
申请人： Airbus Operations SAS , Institut National des Sciences Appliquées de Toulouse (INSAT) , Centre National de la Recherche Scientifique (CNRS) , Université Toulouse III - Paul Sabatier (UT3) , Institut Supérieur de l'Aéronautique et de l'Espace (ISAE) , École nationale supérieure des Mines d'Albi - Carmaux (IMT Mines ALBI)
发明人： Arnaud BOURHIS , Younes RAFIK , Valerian PALANQUE , Valérie POMMIER BUDINGER , Marc BUDINGER , Brice SAUDEL , Yves CLERGENT , Philippe OLIVIER
摘要： A de-icing element having a skin with a surface to be de-iced, at least one excitation actuator attached to the skin, the excitation actuator configured to excite the skin according to at least one predetermined vibration mode generating a deformation of the skin, the deformation of the skin comprising at least one antinode and one node. The skin having a characteristic thickness generally constant with, locally, at least one thickness variation that is localized according to the predetermined vibration mode or modes.
-
公开(公告)号：US20230340149A1
公开(公告)日：2023-10-26
申请号：US18044216
申请日：2021-09-06
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ TOULOUSE III - PAUL SABATIER , ECOLE NATIONALE VÉTÉRINAIRE DE TOULOUSE , INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE)
IPC分类号： C07K16/36 , A61K38/57 , A61P1/04 , C12N15/113 , C12N15/115 , A61K35/741
CPC分类号： C07K16/36 , A61K38/57 , A61P1/04 , C12N15/1137 , C12N15/115 , A61K35/741 , C07K2317/76 , C12N2310/14 , C12N2310/11 , C12N2310/531
摘要： Inventor's general objective was to investigate the potential role of mucosal thrombin in intestinal inflammation and its mechanisms of action. First, they evaluated whether there is an increased presence of active thrombin in Crohn's Disease (CD): both in patient tissues and in an animal models of IBD. Second, they investigated the effects on mucosal damage and tissue dysfunction resulting from the intracolonic administration of thrombin at a dose comparable to what was detected in the tissue of CD patients. Third, they demonstrated in IBD mouse model that pharmacological inhibition of mucosal thrombin activity is a new therapeutic approach to this debilitating condition, such inhibition, allows to significantly decrease all inflammatory parameters including the fecal bleeding score. Finally, inventors showed that human mucosa-associated commensal biofilms exposed to increasing concentrations of human thrombin exhibited increase in their virulent properties specifically, increased bacterial invasion into human epithelial cell line). So, the present invention relates to a method for preventing or treating inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC) by targeting locally the mucosal Thrombin.
-
公开(公告)号：US20230226027A1
公开(公告)日：2023-07-20
申请号：US18001147
申请日：2021-06-11
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , ECOLE NATIONALE VÉTÉRINAIRE DE TOULOUSE , INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT , UNIVERSITÉ TOULOUSE III - PAUL SABATIER
IPC分类号： A61K31/4365 , A61P31/14
CPC分类号： A61K31/4365 , A61P31/14
摘要： Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new beta-coronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that an inhibitor of EPAC1 (i.e. AM-001) is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.
-
公开(公告)号：US11692045B2
公开(公告)日：2023-07-04
申请号：US17028070
申请日：2020-09-22
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , Université Toulouse III—Paul Sabatier , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
IPC分类号： C07K16/40 , C12N15/113 , C12N15/115 , C12Q1/37 , A61K38/57 , C12N9/00 , C12N9/48 , A61P1/04 , A61K39/00
CPC分类号： C07K16/40 , A61K38/57 , A61P1/04 , C12N9/00 , C12N9/48 , C12N15/115 , C12N15/1137 , C12Q1/37 , A61K2039/505 , C07K2317/76 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2310/16 , G01N2333/96433 , G01N2500/02 , G01N2500/10 , G01N2800/065
摘要： The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.
-
公开(公告)号：US20220404124A1
公开(公告)日：2022-12-22
申请号：US17776412
申请日：2020-11-19
申请人： UNIVERSITÉ TOULOUSE III - PAUL SABATIER , COMPOSITES EXPERTISE & SOLUTIONS , COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
摘要： A device for protecting a mobile or static structure against the blast from an explosion or detonation and associated projections of material. The device includes a protective casing made of several materials, the protective casing being located at a distance from the structure to be protected and connected to the structure by an elastomer connection. The protective casing is elastically deformable so as to be able to deform elastically for the duration of the stress by oscillating to spread the energy of the blast from the explosion over its surface and over time in several directions, and then to return completely or partially to its original shape after a period of time.
-
公开(公告)号：US20210040215A1
公开(公告)日：2021-02-11
申请号：US17036763
申请日：2020-09-29
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , Université Toulouse III - Paul Sabatier , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
发明人： Thierry LEVADE , Nicolas MEYER , Céline COLACIOS VIATGÉ , Caroline IMBERT , Nathalie ANDRIEU-ABADIE , Bruno SEGUI
IPC分类号： C07K16/28 , A61K31/133 , G01N33/574 , G01N33/569 , A61P35/00 , A61K45/06 , A61K39/395 , A61K31/4535 , A61K31/4245 , A61K31/426 , A61K31/415 , A61K31/40 , A61K31/137
摘要： The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.
-
公开(公告)号：US20220265731A1
公开(公告)日：2022-08-25
申请号：US17625220
申请日：2020-07-07
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ TOULOUSE III - PAUL SABATIER , ECOLE NATIONALE VÉTÉRINAIRE DE TOULOUSE , INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
IPC分类号： A61K35/741 , C12N9/48 , A61P1/00 , C12N1/20
摘要： The invention relates to the field of modified Escherichia coli strain Nissle 1917 (EcN) and its use for treating gastro-in-testinal disorders. The invention is based on the study of the mechanisms implicated in the probiotic properties of the Escherichia coli strain Nissle 1917 (EcN). This study has allowed the inventors to decouple the probiotic activity of EcN from its genotoxic activity by demonstrating that EcN ClbP protein, the enzyme that activates the genotoxin colibactin, is also required for the siderophore-microcins activity of probiotic EcN, but interestingly, not its enzymatic domain that cleaves precolibactin to form active colibactin. Furthermore, inventors demonstrate in an in vivo animal model infected by a bacterial pathogen that administration of an EcN modified strain with clbP gene encoding ClbP protein inactive for the peptidase domain, is non-genotoxic (do not produce colibactin) but keeps the bacterial antagonist activity, and reduces colonization and virulence of the pathogen by maintaining the siderophore-microcin production. Thus this study opens the way to safe use of EcN and accordingly the present invention provides an Escherichia coli strain Nissle 1917 (EcN) bacterium carrying a gene encoding ClbP protein which is inactive for the peptidase domain, and its use as a drug and more particularly for use in the treatment of gastro-intestinal disease.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.036 秒)
